Drug Profile
BMS 986192
Alternative Names: [18F]BMS-986192; Anti-PD-L1 - Bristol-Myers Squibb; BMS-986192Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Netherlands (IV, Infusion)
- 01 Apr 2017 Interim pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
- 01 Jun 2016 Clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Netherlands (IV) (EudraCT2015-004760-11)